FDA Allows Marketing of Brainsway’s TMS for OCD Treatment

The FDA has permitted marketing of Brainsway’s deep transcranial magnetic stimulation (TMS) device for treating obsessive compulsive disorder.

“Transcranial magnetic stimulation has shown its potential to help patients suffering from depression and headaches,” said Carlos Peña, director of CDER’s Division of Neurological and Physical Medicine Devices. “With today’s marketing authorization, patients with OCD who have not responded to traditional treatments now have another option.”

The agency said the device should not be used by patients with metallic objects or implants that are in or near the head, such as cochlear implants, aneurysm clips or coils or deep brain stimulators.